The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy

Mayo Clinic Proceedings

Volumn 80, Issue 3, 2005, Pages 379-388

  Epstein, Solomon ^a,b,c,d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Doylestown Hospital   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; DEOXYPYRIDINOLINE; IBANDRONIC ACID; INCADRONIC ACID; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID;

BONE DENSITY; BONE MINERALIZATION; BONE STRENGTH; BONE TURNOVER; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORTICAL BONE; DECISION MAKING; FRACTURE; FRACTURE REDUCTION; GEOMETRY; HIP; HORMONAL THERAPY; HUMAN; META ANALYSIS; NONHUMAN; OSTEOLYSIS; OSTEOMALACIA; OSTEOPOROSIS; OVARIECTOMY; PREMENOPAUSE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; VERTEBRA FRACTURE;

EID: 14644401066     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/80.3.379     Document Type: Review

References (98)

1. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement. 2000 March 27-29;17(1):1-36.
2. McClung MR. Bisphosphonates in osteoporosis: recent clinical experience. Expert Opin Pharmacother. 2000;1:225-238.
3. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, Osteoporosis Methodology Group, Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis, IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23:570-578.
4. Wehren LE, Hosking D, Hochberg MC. Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis. Curr Med Res Opin. 2004;20:525-531.
5. Bouxsein ML. Bone quality: where do we go from here? Osteoporos Int. 2003;14(suppl 5):118-127.
6. Parfitt AM. Use of bisphosphonates in the prevention of bone loss and fractures. Am J Med. 1991;91(5B):42S-46S.
7. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res. 1996;11:1531-1538.
8. Bauer DC, Black DM, Garnero P, et al, Fracture Intervention Trial Study Group. Change in bone turnover and hip, non-spine and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004;19:1250-1258.
9. Miller PD, Baran DT, Bilezikian JP, et al. Practical clinical application of biochemical markers of bone turnover: consensus of an expert panel. J Clin Densitom. Fall 1999;2:323-342.
10. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int. 2001;12:922-930.
11. Eastell R, Barton I, Hannon RA, Chines A, Gamero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18:1051-1056.
12. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87:1586-1592.
13. Delmas PD. Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis. Bone. 2002;30:14-17.
14. Rossouw JE, Anderson GL, Prentice RL, et al, Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
15. Ott SM, Oleksik A, Lu Y, Harper K, Lips P. Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. J Bone Miner Res. 2002;17:341-348.
16. Reginster J, Minne HW, Sorensen OH, et al, Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11:83-91.
17. Harris ST, Watts NB, Genant HK, et al, Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282:1344-1352.
18. Ettinger B, Black DM, Mitlak BH, et al, Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial [published correction appears in JAMA. 1999;282:2124]. JAMA. 1999;282:637-645.
19. Rizzoli R, Greenspan SL, Bone G III, et al, Alendronate Once-Weekly Study Group. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res. 2002;17:1988-1996.
20. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994;79:1693-1700.
21. Bauer D, Santora A, Hochberg M, Melton M, Ross P. Alendronate reduces fracture risk in lowest bone turnover group [abstract]. Bone. 2004; 34(suppl 1):S92. Abstract 77.
22. Hosking D, Emkey R, Santora AC, Liberman UA. Fracture risk remains reduced in patients with lowest bone turnover after 10 years of alendronate treatment [abstract]. Proceedings of Endocrine Society Annual Meeting 2004. Available at: www.abstracts2view.com/endo/sessionindex.php?p=2 (abstract #P2-519). Accessed September 15, 2004.
23. Recker R, Ensrud K, Diem S, et al. Normal bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women. J Bone Miner Res. 2004;19(suppl 1):S45.
24. Peter CP, Cook WO, Nunamaker DM, Provost MT, Seedor JG, Rodan GA. Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res. 1996;14:74-79.
25. Bone HG, Hosking D, Devogelaer JP, et al, Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189-1199.
26. Abbott S, Trinkaus E, Burr DB. Dynamic bone remodeling in later Pleistocene fossil hominids. Am J Phys Anthropol. 1996:99:585-601.
27. Heaney RP. Remodeling and skeletal fragility. Osteoporos Int. 2003;14(suppl 5):12-15.
28. Heaney RP. Is the paradigm shifting? Bone. 2003;33:457-465.
29. Parfitt AM. What is the normal rate of bone remodeling? Bone. 2004;35:1-3.
30. Parfitt AM. Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens. 2003;12:387-403.
31. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001;28:524-531.
32. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15:613-620.
33. Komatsubara S, Mori S, Mashiba T, et al. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res. 2004;19:999-1005.
34. Parfitt AM. Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. Bone. 2002;30:5-7.
35. Weinstein RS. True strength. J Bone Miner Res. 2000;15:621-625.
36. Solomon CG. Bisphosphonates and osteoporosis. N Engl J Med. 2002;346:642.
37. Ammann P, Rizzoli R. Bone strength and its determinants. Osteoporos Int. 2003;14(suppl 3):13-18.
38. Cheng XG, Lowet G, Boonen S, et al. Assessment of the strength of proximal femur in vitro: relationship to femoral bone mineral density and femoral geometry. Bone. 1997;20:213-218.
39. Hayes WC, Myers ER. Biomechanics of fractures. In: Riggs BL, Melton LJ III, eds. Osteoporosis: Etiology, Diagnosis, and Management. 2nd ed. Philadelphia, Pa: Lippincott-Raven; 1995:93-114.
40. Balena R, Toolan BC, Shea M, et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest. 1993;92:2577-2586.
41. Lalla S, Hothorn LA, Haag N, Bader R, Bauss F. Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporos Int. 1998;8:97-103.
42. Bauss F, Lalla S, Endele R, Hothorn LA. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol. 2002;29:2200-2208.
43. Schott AM, Cormier C, Hans D, et al. How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. Osteoporos Int. 1998;8:247-254.
44. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254-1259.
45. Meunier PJ, Delmas PD, Eastell R, et al, International Committee for Osteoporosis Clinical Guidelines. Diagnosis and management of osteoporosis in postmeopausal women: clinical guidelines. Clin Ther. 1999;21:1025-1044.
46. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000;85:231-236.
47. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281-289.
48. Hochberg MC, Ross PD, Black D, et al, Fracture Intervention Trial Research Group. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum. 1999;42:1246-1254.
49. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002;17:1-10.
50. Black DM, Thompson DE, Bauer DC, et al, FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial [published correction appears in J Clin Endocrinol Metab. 2001;86:938]. J Clin Endocrinol Metab. 2000;85:4118-4124.
51. Levis S, Quandt SA, Thompson D, et al, FIT Research Group. Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. J Am Geriatr Soc. 2002;50:409-415.
52. Watts NB, Josse RG, Hamdy RC, et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2003;88:542-549.
53. Pols HA, Felsenberg D, Hanley DA, et al, Foxamax International Trial Study Group. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int. 1999;9:461-468.
54. Dempster DW. The impact of bone turnover and bone-active agents on bone quality: focus on the hip. Osteoporos Int. 2002;13:349-352.
55. Kleerekoper M, Dickie D, Feldkamp LA, Goldstein SA, Flynn MJ, Parfitt AM. Cancellous bone architecture and bone strength. In: Christiansen C, Johansen C, Riis BJ, eds. Osteoporosis. Copenhagen, Denmark: Osteopress ApS; 1987:294-300.
56. Wachter NJ, Krischak GD, Mentzel M, et al. Correlation of bone mineral density with strength and microstructural parameters of cortical bone in vitro. Bone. 2002;31:90-95.
57. Turner CH. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int. 2002;13:97-104.
58. Bell KL, Loveridge N, Jordan GR, Power J, Constant CR, Reeve J. A novel mechanism for induction of increased cortical porosity in cases of intracapsular hip fracture. Bone. 2000;27:297-304.
59. Borah B, Dufresne TE, Chmielewski PA, Gross GJ, Gross MC, Phipps RJ. Architecture is one of the determinants of bone strength [letter]. J Bone Miner Res. 2003;18:385.
60. Borah B, Dufresne TE, Chmielewski PA, Gross GJ, Prenger MC, Phipps RJ. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res. 2002;17:1139-1147.
61. Ding M, Day JS, Burr DB, et al. Canine cancellous bone microarchitecture after one year of high-dose bisphosphonates. Calcif Tissue Int. 2003;72:737-744.
62. Recker R, Masarachia P, Santora A, et al. Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin. 2005;21:185-194.
63. Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone. 2004;34:736-746.
64. Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone. 2001;29:185-191.
65. Tami AE, Nasser P, Verborgt O, Schaffler MB, Knothe Tate ML. The role of interstitial fluid flow in the remodeling response to fatigue loading. J Bone Miner Res. 2002;17:2030-2037.
66. Burr DB. Targeted and nontargetėd remodeling. Bone. 2002;30:2-4.
67. Martin RB. Is all cortical bone remodeling initiated by microdamage? Bone. 2002;30:8-13.
68. Mori S, Harruff R, Ambrosius W, Burr DB. Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures. Bone. 1997;21:521-526.
69. Ciarelli TE, Fyhrie DP, Parfitt AM. Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females. Bone. 2003;32:311-315.
70. Whyte MP. Sclerosing bone disorders. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999:367-383.
71. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-342.
72. Klein RF, Allard J, Avnur Z, et al. Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science. 2004;303:229-232.
73. Roschger P, Fratzl P, Klaushofer K, Rodan G. Mineralization of cancellous bone after alendronate and sodium fluoride treatment: a quantitative backscattered electron imaging study on minipig ribs. Bone. 1997;20:393-397.
74. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. 2000;27:687-694.
75. Roschger P, Gupta HS, Berzlanovich A, et al. Constant mineralization density distribution in cancellous human bone. Bone. 2003;32:316-323.
76. Burr DB, Miller L, Grynpas M, et al. Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone. 2003;33:960-969.
77. Boivin G, Meunier PJ. Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tissue Res. 2002;43:535-537.
78. Meunier PJ, Boivin G. Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications. Bone. 1997;21:373-377.
79. Follet H, Boivin G, Rumelhart C, Meunier PJ. The degree of mineralization is a determinant of bone strength: a study on human calcanei. Bone. 2004;34:783-789.
80. Thomsen JS, Ebbesen EN, Mosekilde L. Predicting human vertebral bone strength by vertebral static histomorphometry. Bone. 2002;30:502-508.
81. Hayes WC, Shea M, Rodan GA. Preclinical evidence of normal bone with alendronate. Int J Clin Pract Suppl. 1999;101:9-13.
82. Actonel [package insert]. Mason, OH; Procter & Gamble Pharmaceuticals, Inc; 2004.
83. Fosamax [package insert]. Whitehouse Station, NJ; Merck & Co, Inc; 2004.
84. Guyatt GH. Evidence-based management of patients with osteoporosis. J Clin Densitom. 1998;1:395-402.
85. Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-Based Medicine: How to Practice and Teach EBM. 2nd ed. New York, NY: Churchill Livingstone; 2000:173-177.
86. Majumdar S, Link TM, Augat P, et al, Magnetic Resonance Science Center and Osteoporosis and Arthritis Research Group. Trabecular bone architecture in the distal radius using magnetic resonance imaging in subjects with fractures of the proximal femur. Osteoporos Int. 1999;10:231-239.
87. Kleerekoper M, Villanueva AR, Stanciu J, Rao DS, Parfitt AM. The role of three-dimensional trabecular microstructure in the pathogenesis of vertebral compression fractures. Calcif Tissue Int. 1985;37:594-597.
88. Ciarelli TE, Fyhrie DP, Schaffler MB, Goldstein SA. Variations in three-dimensional cancellous bone architecture of the proximal femur in female hip fractures and in controls. J Bone Miner Res. 2000;15:32-40.
89. Mayhew P, Kaptoge S, Loveridge N, et al. Discrimination between cases of hip fracture and controls is improved by hip structural analysis compared to areal bone mineral density: an ex vivo study of the femoral neck. Bone. 2004;34:352-361.
90. Qui S, Rao DS, Palnitkar S, Parfitt AM. Reduced iliac cancellous osteocyte density in patients with osteoporotic vertebral fracture. J Bone Miner Res. 2003;18:1657-1663.
91. Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK. Bone loss and bone size after menopause. N Engl J Med. 2003;349:327-334.
92. Moore RJ, Durbridge TC, McNeil PJ, Parkinson IH, Need AG, Vernon-Roberts B. Trabecular spacing in post-menopausal Australian women with and without vertebral fractures. Aust N Z J Med. 1992;22:269-273.
93. Courtney AC, Wachtel EF, Myers ER, Hayes WC. Age-related reductions in the strength of the femur tested in a fall-loading configuration. J Bone Joint Surg Am. 1995;77:387-395.
94. Courtney AC, Wachtel EF, Myers ER, Hayes WC. Effects of loading rate on strength of the proximal femur [published correction appears in Calcif Tissue Int. 1994;55:402]. Calcif Tissue Int. 1994;55:53-58.
95. Bailey AJ, Sims TJ, Ebbesen EN, Mansell JP, Thomsen JS, Mosekilde L. Age-related changes in the biomechanical properties of human cancellous bone collagen: relationship to bone strength. Calcif Tissue Int. 1999;65:203-210.
96. Lin JC, Grampp S, Link T, et al. Fractal analysis of proximal femur radiographs: correlation with biomechanical properties and bone mineral density. Osteoporos Int. 1999;9:516-524.
97. Barton S. Which clinical studies provide the best evidence? the best RCT still trumps the best observational study [editorial]. BMJ. 2000;321:255-256.
98. Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone. 2003;32:120-126.